



The prevalence of chronic obstructive pulmonary disease 
(COPD) in Europe is estimated to be as high as 4–10% of 
the adult population [1,2]. The disease has a detrimental 
impact on quality and length of life of affected individuals, 
as well as on population health status. It is estimated to be 
the 5th leading cause of mortality worldwide, and is pro-
jected to rank 3rd by 2020 [3]. Chronic obstructive pulmo-
nary disease also results in noticeable consumption of health 
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care resources [4]. As a consequence, COPD causes a large, 
though not yet precisely estimated, economic burden [5]. 
Despite its paramount medical, social and economic conse-
quences, public awareness of COPD is alarmingly low [3]. 
A substantial percentage of COPD patients either do not re-
ceive proper medical diagnosis or are not diagnosed until the 
late stages of the disease [6].
Only a few studies have assessed the prevalence of COPD 
in Poland [7-9], and the estimates varied widely, ranging from 
8.5% in men and 4.9 in women [7] up to 10.7% in both sexes 
in an urban adult population [8,9]. A limitation of the Polish 
and international literature on COPD is that comparison of 
prevalence estimates is limited by variation in: the definitions 
of COPD used, the populations studied, and sampling meth-
odologies used [7-10]. In particular, prevalence assessments 
can be based on self-reported medical diagnosis, spirometry 
and/or questionnaires. The Global Obstructive Lung Dis-
ease (GOLD) Initiative has helped to alleviate this problem 
through its proposed and widely adopted system for the defini-
tion and classification of COPD [3]. More recently the Burden 
of Obstructive Lung Disease (BOLD) study was started in an 
attempt to provide a standardized framework for estimating 
(using the GOLD criteria) the prevalence of COPD and its 
risk factors, along with an estimate of the economic burden of 
COPD, in different countries around the world [11].
In this paper we report on the implementation of the 
BOLD protocol in a population-based sample of residents of 
the Malopolska region in southern part of Poland. We present 
data on the prevalence of COPD and selected risk factors (par-
ticularly smoking) in this population. This report expands on 
data recently presented as part of an international comparison 
of COPD prevalence among participating twelve BOLD sites 
[12].
PATIENTS	AND	METHODS
The study was performed using the BOLD methodology 
as briefly described below. Further details about the design 
and rationale of BOLD and its primary results are available 
elsewhere [11,12].
Participants
The target population (172,667 individuals) consisted of 
residents of the two districts (Chrzanow and Proszowice) of 
the Malopolska region in southern Poland. Using information 
from current census data, we conducted an age-gender strati-
fied random sample of 800 adults aged 40 years and older in 
an attempt to recruit 600 study participants. Institutionalized 
individuals were excluded, as were those precluded from lung 
function testing for safety reasons.
Examinations
Study measurements consisted of a series of questionnaires 
and objective measurement of lung function (spirometry). The 
questionnaire data included information about respiratory 
symptoms, activity limitation, diagnosed airways diseases, to-
bacco smoke exposure, health status, use of biomass fuels for 
cooking or heating, and occupational exposures.
Spirometry was performed according to American Thorac-
ic Society (ATS) guidelines [13] using ATS-certified, portable, 
battery operated, ultrasound-based spirometer (EasyOneTM; 
ndd Medical Technologies, Chelmsford MA, USA, and Zur-
ich, Switzerland). The procedure, which was performed with 
participants in the seated position and wearing nose clips, was 
done before and at least 15 minutes after administration of 
400 mcg of a bronchodilator (salbutamol) via metered-dose 
inhaler with a spacer (Volumatic; GlaxoSmith-Kline; Research 
Triangle Park, NC). Spirometers were calibrated on each study 
day using a 3.00-liter syringe. If the quality of spirometry (as 
accessed automatically by the spirometer) had not been satis-
factory, the maneuver was repeated until the technician judged 
that the best quality for a given subject was obtained (up to 10 
times). During the study, spirometry data were periodically 
transferred to the Pulmonary Function Reading Center (Salt 
Lake City, UT, USA) where they were individually reviewed 
and graded; only spirometries fulfilling ATS quality criteria 
[13] were included into analysis. Height was measured using 
portable stadiometers.
Study technicians were trained and certified at the outset 
of the study and their work was carefully supervised during the 
study. Those who failed to produce acceptable quality results 
were temporarily removed from the study until re-trained and 
re-certified. Interviews and examinations were performed ei-
ther in local field centers or in participants’ houses as needed.
Summary spirometry measures reported here include the 
one-second forced expiratory volume (FEV1), the forced vital 
capacity (FVC), and their ratio FEV1/FVC. Both FEV1 and 
FVC were measured as the maximum value from among ac-
ceptable maneuvers, while FEV1/FVC was defined as the sim-
ple ratio of these two measures.
Definitions
COPD and its stages were defined according to GOLD 
guidelines. All stages refer to post-bronchodilator values: 
Stage 1: FEV1/FVC <0.7 and FEV1 ≥80% predicted; Stage 2: 
FEV1/FVC <0.7, FEV1 ≥50 and <80% predicted; Stage 3: 
FEV1/FVC <0.7 and FEV1 ≥30 and <50%; Stage 4: FEV1/
FVC <0.7 and FEV1 <30% predicted [3]. The third United 
States National Health and Nutrition Examination Study 
(NHANES III) reference values for Caucasian men and wom-
en [14] were used to obtain predicted lung function measure-
ments (BOLD uses a common set of prediction equations 
to facilitate cross-site comparisons). Education level data were 
based on self-reported years of education and classified accord-
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ing to education system in Poland as low (≥8 years), middle 
(9–12 years) and high (>12 years).
Statistical analysis
We used SAS software package (SAS Institute, Cary, NC), 
version 9.1, for database management and statistical analysis. 
We compared means and proportions by standard normal z-test 
and the χ2 statistic, respectively. SAS PROC SURVEYMEANS 
procedure was used to derive suitably weighted estimates 
(and standard errors) of continuous traits and proportions 
for the combined populations of Chrzanow and Proszowice 
as a whole. For binary response variables in order to check 
for the linearity of relations, with or without adjustment for 
possible confounders, we used logistic regression as supplied 
in PROC LOGISTICS procedure with appropriate weighting. 
In the sensitivity analyses, we additionally adjusted the log-
linear models for the area of recruitment.
Ethical issues
The study was approved by the Bioethics Committee of 
the Jagiellonian University Medical School, Krakow. All par-
ticipants gave written, informed consent.
RESULTS
Among the 762 individuals whom we ultimately attempt-
ed to recruit for the study, 603 (79.1%) provided questionnaire 
and post-bronchodilator spirometry, and of this latter group 
526 (87.2%) had acceptable quality spirometry data and were 
included in this analysis. Compared to nonresponders, those 
agreeing to participate in the study were significantly older 
and more likely to have ever smoked. In addition, those with 
acceptable quality spirometry were significantly younger than 
responders without acceptable quality spirometry.
The study sample consisted of 266 men and 260 women. 
The mean (±SD) age of the cohort was 55.7 ±11.5 years and 
did not differ significantly between men and women (Tab. 1). 
Mean years of education (10.5 ±3.4 years) also was similar for 
men and women. However, a history of current or past smok-
ing was significantly greater in men than women (78.9% vs. 
42.1%, p <0.0001). Despite the differences in smoking history 
between men and women, percent of predicted FEV1 and FVC 
did not differ between sexes (Tab. 2). However, FEV1/FVC was 
slightly, though significantly, higher in women.
Sixty percent of the combined population of Chrza now and 
Proszowice aged 40 and older are estimated to be ever-smok-
ers, while the prevalence of current smoking in this population 
is estimated to be 28%. Smoking was more prevalent in men 
than in women (especially among older individuals) (Fig. 1).
Current smoking was common at all education levels, yet 
tended to be slightly higher in middle educated individuals. 
However, no statistically significant trend of change in smok-
ing habit with changing education level was found, either in the 
entire population, or in men and women separately (Fig. 2).
Table 1.  Characteristics of the studied population (unweighted 
data for study sample)
Total Men Women p value*
n 603 303 300
Age, years (%)
40–49 37.5 38.0 39.9
0.67
50–59 27.4 28.2 26.5
60–69 20.3 19.5 21.2
≥70 14.8 14.3 15.4
Smoking status (%)
current smokers 29.1 36.1 21.9
<0.001former smokers 32.3 42.9 21.5
never smokers 38.6 21.0 56.5
Education, years (%)
≤8 34.8 30.8 38.9
0.139–12 40.9 43.6 38.0
>12 24.3 25.6 23.1
* 2-sided p values based on χ2 test
Table 2. Lung function by sex (weighted population estimates)
Post-bronchodilatator values Total Men Women Weighted p*
FEV1 (L)   2.9 (1.0)   3.3 (0.9)   2.4 (0.7) <0.0001
FEV1 (%, predicted ) 94.8 (20.1) 94.5 (20.4) 95.0 (19.8) 0.72
FVC (L)   3.8 (1.1)   4.5 (1.0)   3.1 (0.8) <0.0001
FVC (%, predicted) 97.7 (18.5) 97.8 (16.7) 97.6 (20.3) 0.88
FEV1/FVC (%) 75.1 (9.3) 73.9 (10.0) 76.2 (8.3) 0.005
* 2-sided p values based on z-tests for comparing population-based estimates 
Data expressed as mean (SD). Abbreviations: FEV1 – one-second forced expiratory volume, FVC – forced vital capacity
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Ever-smoking subjects have smoked on average 24.3 pack-
-years (SD 20.4). Men smoked significantly more than women 
(respectively 29.2 vs. 15.1 pack-years, p <0.0001) (Fig. 3).
29.3% of never-smokers, 30.1% of women and 26.8% of 
men were exposed to tobacco smoke in their households dur-
ing the last 2 weeks before the survey was performed. Other 
environmental risk factors will be reported separately.
The estimated prevalence of COPD (GOLD Stages ≥1) 
in Malopolska region was 22.1%, while the prevalence of 
GOLD Stages ≥2 COPD was 10.9%. Almost half of indi-
viduals aged 70 years and older (including three-quarters of 
men in this age group) are estimated to meet GOLD criteria 
for COPD. Chronic obstructive pulmonary disease prevalence 
increased with age in both sexes, and for each age group was 
greater in men than in women (Tab. 3 and 4).
Only 10 individuals met criteria for GOLD Stages 3 or 
4 COPD, with an estimated population prevalence of 1.9% 
(SE 0.6) (3.0% [SE 1.0] in men and 0.8% [SE 0.6] in women).
Prevalence of COPD (GOLD Stage ≥1) and COPD in 
stage ≥2 also increased with increasing pack-years of cigarette 
smoking in men (Fig. 4 and 5). The number of ever-smoking 






























































































Fig. 2. Proportion of current smokers by education level and sex 
































women with COPD (n = 12) made estimations done in wom-
en unreliable.
Prevalence of COPD (GOLD Stage ≥1) and COPD in 
Stage ≥2 decreased with education level (Fig. 6).
In our population, after adjustment for sex, age, and smok-
ing anytime in the lifetime, education higher by one level was 
associated with 35% (95% CI, 10–63, p = 0.009) lower proba-
bility of diagnosing COPD GOLD Stage ≥1, and 35% (95% CI, 
1–68, p = 0.05) lower probability of diagnosing COPD 
GOLD Stage ≥2.
In sensitivity analyses, additional adjustment for region of 
population recruitment did not alter the results.
DISCUSSION
Prevalence of COPD in the studied region of southern 
Poland was found to be very high. Prevalence of all COPD 
i.e. GOLD Stage 1 and higher was 22.1% (27.7% in men and 
16.6% in women), and COPD in GOLD Stage 2 and higher 
constituted about half of these cases (11.9% overall; 13.3% in 
men and 8.6% in women). GOLD Stage 2 and higher COPD 
is often referred to as “clinically significant” COPD in that 
these individuals usually have symptoms of the disease and 
thus need (or will need) medical attention and represent high 
burden of COPD in the coming years in Poland.
Based on census data [15] it can be extrapolated that there 
are about 3,800,000 people in Poland with COPD, with al-
most 2,000,000 suffering from COPD in Stage ≥2. Our results 
are based on population sample from particular two districts 
of Poland and thus cannot be regarded as fully representa-
tive for the country as a whole. However, cultural uniformity 
across Poland, similar smoking patterns [16] and the inclusion 
of participants from both rural and urban areas could par-
tially justify such an approach. Nevertheless, data from simi-
lar studies performed in such methodologically stringent way 
would be welcomed in other regions of Poland.
Results of recently published estimations in adults from 
2 big cities in Poland reported COPD prevalence about 10% 
[8,9]. In a survey of Warsaw city inhabitants aged 40 years 
and older, the reported prevalence of COPD (defined as 
FEV1/FVC <0.7 and presence of COPD symptoms) was 10.7% 
[8]. A second study (using similar criteria to define COPD) 
found a prevalence of 10.2% in the city of Zabrze among sub-
jects older than 18 years [9]. However, both of these stud-
ies presented sample data rather than population estimates. 
An earlier 1981 study of 1864 individuals aged 32 and older 
reported a prevalence of 8.5% in men and 4.9% in women, 
Table 3. Estimated population prevalence of GOLD Stage ≥1 and higher by age and sex
Age (years) 40–49 50–59 60–69 ≥70 Total p for trend
Men 8.0 (2.9) 22.5 (4.8) 40.2 (7.0) 74.2 (7.5) 27.7 (2.4) <0.0001
Women 3.0 (1.7) 10.7 (3.8) 32.1 (5.5) 31.2 (7.1) 16.6 (2.1) <0.0001
Total 5.7 (1.7) 16.8 (3.1) 35.9 (4.4) 49.6 (5.2) 22.1 (1.6) <0.0001
Standard errors shown in parentheses
Table 4. Estimated population prevalence of GOLD Stage≥2 and higher by age and sex
Age (years) 40–49 50–59 60–69 ≥70 Total p for trend
Men 2.1 (1.5 ) 10.4 (3.4) 19.9 (5.5) 40.4 (8.2) 13.3 (1.9) <0.0001
Women 2.0 (1.4)  6.1 (2.9) 15.3 (4.4) 15.8 (5.3)  8.6 (1.7)   0.0005
Total 2.1 (1.0)  8.3 (2.3) 17.5 (3.5) 26.3 (4.7) 10.9 (1.3) <0.0001
Standard errors shown in parentheses
































Fig. 4. Prevalence of GOLD Stage 1 and higher by pack-years and 
sex (weighted population estimates, * p value for trend). COPD – 
chronic obstructive pulmonary disease
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although this was based on a somewhat more stringent defini-
tion of COPD [7]. Despite the fact that our data cannot be 
directly compared with the above results from previous studies 
due to differences in methods used, COPD prevalence reported 
in our study based on region-representative sample in southern 
Poland is higher than expected. This is a piece of information 
of paramount importance, taking into account the significant 
social burden and medical costs of COPD.
Recently published global results of BOLD Study in which 
Poland also participated, have shown COPD prevalence to be 
higher than previously estimated in another eleven countries, 
from Europe, US, Australia and South Africa [12]. Burden of 
Obstructive Lung Disease Study in Austria has brought quite 
similar results to those in Poland (estimated population preva-
lence of COPD in Stage 1 or higher – 26.1% and in Stage 2 or 
higher – 10.7%) [17]. Total proportion of COPD patients is 
similar in Austria and Poland, yet important differences ex-
ist in sex structure of COPD patients. This finding can be 
partially explained by the differences in frequency of smoking 
habit in Poland and Austria (more ever-smoking women in 
Austria). The results of earlier studies assessing COPD preva-
lence in Europe are remarkably different, with lower COPD 
prevalence, ranging from 8 to 14% [18,19]. The study from 
Greece has estimated the prevalence of COPD to be 8.4% in 
smokers older than 35 years old [18], while the OLIN Study 
carried out in Northern Sweden in the population older than 
45 years reported a prevalence of COPD in GOLD Stage ≥1 of 
14% [19]. It should be emphasized, however, that part of the 
discrepancies between all these studies result from the influ-
ence of different COPD definitions on estimated disease prev-
alence as it was demonstrated in the study based on data from 
the NHANES III carried out in the USA [20]. Differences 
in methodology between studies make cross-study compari-
sons unreliable and underline the importance of epidemiologi-
cal studies performed according to common, widely accepted 
methodology, such as BOLD Study.
As expected, COPD prevalence in our study increased 
steeply with age similar to results found in many other coun-
tries using the same BOLD methodology [12] and in many 
other previous epidemiological studies [18,19]. COPD preva-
lence increased also with smoking. However, the latter rela-
tionship was clearly demonstrated in our study only in men. 
Two factors could have influenced this finding. Firstly, the to-
tal burden of tobacco smoke was significantly greater in smok-
ing men than in smoking women in all age groups and it could 
result in higher COPD prevalence in men. Secondly, the ab-
solute number of smoking women with COPD in our sample 
was low, making the analysis of this group difficult.
Prevalence of COPD both in Stage ≥1 (17.8% overall) and 
Stage ≥2 (9.2% overall) in never-smokers, especially in women 
(20.1% in GOLD Stage ≥1 and even 11.2% in GOLD Stage 
≥2), was surprisingly high in our country, much higher in 
comparison to other countries participating in BOLD Study 
[12], indicating the need to investigate for other COPD risk 
factors in this group of women. Some of these COPD cases 
can be explained by the exposure to passive smoking, which 
was found in about 1/3 of non-smoking women. The possible 
explanation for high prevalence of COPD in never-smoking 
women could be also an exposure to other environmental risk 
factors and a greater susceptibility to harmful effect of tobacco 
smoke [21].
In our study COPD prevalence showed marked differences 
across education levels in both sexes; COPD was much more 
prevalent in individuals with the lowest education level. The 
educational level in BOLD methodology was used as a sur-
rogate for socio-economic status. Logistic regression model has 
confirmed education level to be a factor independent from sex, 
age and smoking status in our sample. Education level was 
Fig. 5. Prevalence of GOLD Stage 2 and higher by pack-years and 
sex (weighted population estimates, * p values for trend). Abbre-
viation – see Figure 4
Fig. 6. Prevalence of COPD in GOLD Stage ≥1 and COPD in GOLD 
Stage ≥2, by education level (weighted population estimates, 
* p value for trend). Abbreviation – see Figure 4































































done according to pre-defined BOLD Study methodology 
[11]. On the other hand we had very good response rate, which 
was much higher than in previously reported studies in Poland 
[7-9].
Results of BOLD Study carried out in Poland confirm 
the high prevalence of COPD in Malopolska region of Poland 
and indicate the urgent need for increased efforts to improve 
COPD awareness in health professionals, health authorities 
and general public as well to augment the prevention pro-
grams in Poland.
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shown to be related to COPD prevalence in multiple [22,23] 
but not all studies [24]. Probable explanation for these differ-
ences is that education level actually reflects complex influ-
ences of multiple lifestyle-related risk factors.
Estimated population frequency of COPD in Stage ≥1 in 
our study was very high in subjects aged 70 or more (about 
74% in men and over 31% in women). Using a post-broncho-
dilator fixed FEV1/FVC ratio of less than 0.7 as a threshold for 
COPD diagnosis in this age group can probably lead to overes-
timation of the disease prevalence. A population-based study 
in individuals over 70 years showed FEV1/FVC ratio below 
0.7 in about 35% of asymptomatic, non-smoking subjects 
[25]. Study based on the NHANES III data has shown that 
up to 20% of elderly subjects with FEV1/FVC above 5th per-
centile had FEV1/FVC ratio below 0.7 [26]. However, recent 
study has demonstrated that individuals with FEV1/FVC ra-
tio below 0.7 and above 5th percentile have indeed increased 
risk of COPD-related death or hospitalization [27]. The latter 
finding in part justifies using fixed FEV1/FVC ratio especially 
in epidemiological studies (such as BOLD study), because this 
can help to identify subjects who may need medical attention. 
On the other hand, in our study over 25% of subjects aged 70 
or more had COPD in Stage ≥2, confirming high disease bur-
den in the elderly population. In 2005 census data people >60 
years old constituted 17% of society, but in 2020 this percent-
age is projected to grow up to 26% [15]. This changes in age 
structure of the society alone in Poland will undoubtedly lead 
to further increase in COPD prevalence.
Reported smoking prevalence rate in our study was almost 
28%, which is roughly in concordance with assessment (31%) 
reported in adults by last available government data (Polish 
National Statistics Office) [28]. Prevalence of ever-smoking 
in studied population was almost 60% overall and 78% in 
men. Some recent studies indicate that COPD prevalence in 
smokers may be higher than previously estimated [24] and 
male smokers in our sample had very large burden of almost 
30 pack-years. Moreover, the results from a spirometry-based 
COPD screening program in Poland performed in smokers 
older than 40 years have already demonstrated a 30% fre-
quency of airway obstruction [29]. Similar results were found 
in a screening program done before 2000 in the Proszowice 
district of the Malopolska region where part of our study was 
carried out [30].
Thus, every effort should be placed on smoking cessation 
programs. The prevalence of continued use of tobacco in Po-
land is decreasing, however, significant smoking burden in the 
past will increase even more the effect of aging of Polish pop-
ulation on future COPD occurrence. Unfortunately, positive 
changes in smoking prevalence were observed recently mainly 
in men (9% drop in smoking rate for the last 8 years) while in 
women smoking rate is almost similar for the last years (ca 1% 
decrease) [15]. In our study we have found remarkably higher 
percentage of smokers in women aged 40–60 years than in 
older groups. This can lead to a possible further increase in 
COPD prevalence in women.
The limitation of our study was relatively small sample 
size, however, this made the study easier to perform and was 
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